The Medical Letter on Drugs and Therapeutics
AspireAssist - A New Device for Weight Loss
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved AspireAssist (Aspire Bariatrics), a weight-loss device that permits patients to drain a portion of their stomach contents through a gastrostomy tube into a toilet after each meal. It is approved for long-term use in combination with lifestyle modifications in adults ≥22 years old who have a body mass index (BMI) of 35 to 55 and have not been able to achieve and maintain weight loss with nonsurgical therapy.

WEIGHT LOSS PROCEDURES — Surgical treatment of obesity is generally limited to patients with a BMI ≥40, or a BMI ≥35 with an obesity-related comorbidity such as diabetes, hypertension, or hypercholesterolemia. Procedures that cause malabsorption (Roux-en-Y gastric bypass and biliopancreatic diversion) lead to greater weight loss, but more adverse effects, than purely restrictive procedures such as adjustable gastric banding or sleeve gastrectomy. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: AspireAssist - A New Device for Weight Loss
Article code: 1502a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian